Table 1. TLR9 and TLR7 agonists in development for asthma.

Company

Product

Description

Status

Cytos Biotechnology AG (SIX:CYTN)

CYT003

Virus-like particle containing an oligonucleotide agonist of
toll-like receptor 9 (TLR9)

Phase II

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

GSK2245035

TLR7 agonist

Phase II

AstraZeneca plc (LSE:AZN; NYSE:AZN)/Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506)

AZD8848

Inhaled TLR7 agonist

Phase I

Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

IMO-2134

TLR9 agonist

Phase I

Dynavax Technologies Corp. (NASDAQ:DVAX)/AstraZeneca

AZD1419

TLR9 agonist

Preclinical

InDex Pharmaceuticals AB

DIMS 9054

DNA-based immunomodulatory sequence (DIMS) binding to TLR9

Preclinical